# About Medicine NAD: An Independent NAD+ Research Digest

> Medicine NAD is an independent editorial project that publishes cited summaries of the peer-reviewed NAD+ literature. Not a clinic, not a vendor, no medical advice.

An independent editorial reading of the NAD+ literature, built as a precise reference, not a storefront.

## What This Project Is

Medicine NAD is an independent editorial project that publishes summaries of the peer-reviewed research literature on NAD+ — nicotinamide adenine dinucleotide — and its precursors. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The approach is deliberately plain: read the studies, report what they measured, keep the units and the species and the route attached to every number, and cite the source. NAD+ is a topic where search results blur distinctions the science keeps separate — the coenzyme versus its precursors, oral versus intravenous, blood-NAD+ elevation versus a proven clinical outcome. The point of this digest is to keep those distinctions sharp.

## About the Name

The word "medicine" in the name is editorial framing — the register of a reference monograph, the position this publisher occupies relative to the biochemistry literature. It is not a claim about services. This site does not prescribe, does not offer telehealth, does not sell NAD+ or any precursor, and does not represent that an approved "NAD+ drug" or a prescribing pathway exists. NAD+ is sold as a dietary supplement; intravenous NAD+ is an unapproved compounded therapy. We describe what the research shows, and nothing more.

## How We Handle Evidence

Every quantitative claim here maps to a numbered citation on the references page, drawn from PubMed-indexed journals and reviews. We distinguish what is well established (oral precursors raise blood NAD+) from what remains open (whether that translates into hard human clinical outcomes), and we flag the documented risks — including the FDA Class I recall of a compounded NAD+ injection — where they are relevant. When the evidence stops, we say so rather than fill the gap.

The house style is deliberately conservative with framing and precise with numbers. A dose is reported with its species, route and duration attached. A precursor trial is never described as "taking NAD+," because the molecules and their bioavailability differ. A biomarker change (blood NAD+ rising) is never upgraded into a clinical claim (a disease prevented). This restraint is the point of a reference monograph: a reader should be able to take any figure on this site, find it in the cited source, and see exactly what was measured and in whom.

## What We Do Not Do

We do not recommend that anyone take NAD+, NMN, NR, or any supplement, and we publish no dosing instructions. We do not name or endorse commercial brands. We do not offer consultations, prescriptions, or telehealth, and we hold no view on any vendor or clinic. NAD+ is not an approved medicine, and we do not imply that a prescribing pathway for an approved "NAD+ drug" exists. For decisions about your own health, the right source is a qualified clinician who knows your history — not a literature digest.

---

A ruled reading of the NAD+ literature — the coenzyme kept distinct from its precursors, the measured separated from the unproven; not a clinic, not a vendor, not a prescription.